Related Experiment Videos
[Anti-androgen withdrawal syndrome]
1Urologische Klinik und Poliklinik, Technischen Universität München, Klinikum rechts der Isar.
Der Urologe. Ausg. A
|May 1, 1998
Summary
Withdrawing antiandrogens in advanced prostate cancer patients can improve outcomes. This strategy may lead to PSA reduction and clinical benefits in 30-50% of cases.
Area of Science:
- Oncology
- Urology
Context:
- Androgen deprivation therapy (ADT) is standard for incurable prostate cancer.
- Antiandrogens are used alone or with other treatments like GnRH analogs or orchiectomy.
Purpose:
- To evaluate the impact of antiandrogen withdrawal in patients progressing on ADT.
Summary:
- Withdrawal of antiandrogens in hormone-resistant prostate cancer may cause PSA reduction and clinical improvement.
- In 30-50% of patients, this strategy can lead to a PSA decrease lasting about 6 months.
- Some patients experience symptom improvement and objective remission.
Impact:
- Suggests a potential therapeutic strategy for managing treatment-resistant prostate cancer.
- Offers a clinical approach to potentially improve patient outcomes and quality of life.